The Biden administration and other governments around the world have bet big on Pfizer’s Covid-19 pill, Paxlovid (Nirmatrelvir/Ritonavir). The administration touts widespread availability, and White House Covid czar Ashish Jha says that it’s “good news” that people are using it more.
But despite ringing endorsements for Paxlovid, what remains under-discussed is the lack of available data about how well it works in the populations using it. Since the drug costs the government more than $500 per treatment course, this lack of data means that we have no way to evaluate whether Americans are getting a fair deal.
Read Full Article »